05 influenza grohskopf 508
Document text
National Center for Immunization & Respiratory Diseases Influenza B/Yamagata Update Lisa Grohskopf, MD, MPH Advisory Committee on Immunization Practices February 28, 2024 •Quadrivalent influenza vaccines introduced in 2013 -14 to provide broader coverage of influenza B viruses. –Quadrivalents contain one influenza B virus from each lineage (Victoria and Yamagata). –Transition from trivalents to quadrivalents complete by the 2021 -22 influenza season. •No confirmed influenza B/Yamagata viruses in global surveillance since March 2020. •WHO and the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) have recommended excluding B/Yamagata from influenza vaccines. •WHO has made recommendations for Northern Hemisphere 2024 -25 vaccines. –Decisions regarding composition are made by individual national regulatory authorities. •VRBPAC to discuss composition of 2024- 25 U.S. influenza vaccines on March 5, 2024. Influenza B/Yamagata and 2024 -25 Influenza Vaccines 2Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season (who.int) Vaccines and Related Biological Products Advisory Committee October 5, 2023 Meeting Announcement - 10/05/2023 | FDA Recommended composition of influenza virus vaccines for use in the 2024 -2025 northern hemisphere influenza season (who.int) Vaccines and Related Biological Products Advisory Committee March 5, 2024 Meeting Announcement - 03/05/2024 | FDA For more information, contact CDC 1-800- CDC- INFO (232- 4636) TTY: 1 -888- 232- 6348 www.cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.